InvestorsHub Logo
Followers 21
Posts 1331
Boards Moderated 1
Alias Born 07/02/2013

Re: None

Thursday, 08/08/2013 7:06:02 AM

Thursday, August 08, 2013 7:06:02 AM

Post# of 1309
Q1 details -must know if you are taking a call

number of patients with Secondary Progressive Multiple Sclerosis in the United States of America Is presently 150,000 and at the present treatment cost, this represent a $7.5 billion revenue opportunity or sales opportunity for Tcelna

http://www.earningsimpact.com/Transcript/82774/OPXA/Opexa-Therapeutics-Inc----Q1-2013-Earnings-Call